Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · see citing works

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · see citing works

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works

Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas

Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,067 · see citing works

Tumor spectrum analysis in p53-mutant mice

Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · see citing works

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987 · see citing works

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · see citing works

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814 · see citing works

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works

Unravelling mechanisms of p53-mediated tumour suppression

Bieging-Rolett, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3711 · Cited by 1,389 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210 · see citing works

P53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065 · see citing works

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033 · see citing works

Role of Tyrosine Kinase Inhibitors in Cancer Therapy

Arora, A., & Scholar, E. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,013 · see citing works

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Heise, C. C., Sampson-Johannes, A., Williams, A., McCormick, F. P., Hoff, D. D. V., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 941 · see citing works

Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression

Kern, S. E., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K. W., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940 · see citing works

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802 · see citing works

Mutant p53 drives invasion by promoting integrin recycling

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796 · see citing works

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 786 · see citing works

Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53

Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 731 · see citing works

<i>TP53</i>Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721 · see citing works

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

Eliyahu, D., Raz, A., Gruß, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 706 · see citing works

Wild-type p53 can inhibit oncogene-mediated focus formation.

Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 681 · see citing works

The mitochondrial p53 pathway

Vaseva, A. V., & Moll, U. M. (2008) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 618 · see citing works

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612 · see citing works

tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors

Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D. S., Kutok, J. L., Fletcher, C. D. �., Morris, J. P., Liu, T. X., Schulte‐Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 599 · see citing works

Tumor Suppressive Functions of p53Preprint

Zilfou, J. T., & Lowe, S. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001883 · Cited by 572 · see citing works

The expanding universe of p53 targets

Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

An inherited <i>p53</i> mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma

Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541 · see citing works

Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 538 · see citing works

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome

Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534 · see citing works

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533 · see citing works

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493 · see citing works

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 472 · see citing works

Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer

Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 471 · see citing works

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · see citing works

Targeting the ERBB family in cancer: couples therapy

Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464 · see citing works

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53

Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453 · see citing works

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 442 · see citing works

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439 · see citing works

Tumour-associated mutant p53 drives the Warburg effect

Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · see citing works

Small peptides activate the latent sequence-specific DNA binding function of p53

Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 433 · see citing works

Structure–function–rescue: the diverse nature of common p53 cancer mutants

Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 430 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

The role of mutant p53 in human cancer

Goh, A. M., Coffill, C. R., & Lane, D. P. (2010) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398 · see citing works

High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene

Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T. J., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 393 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

The first five years of single-cell cancer genomics and beyondPreprint

Navin, N. E. (2015) · Genome Research · doi:10.1101/gr.191098.115 · Cited by 368 · see citing works

p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis

Kemp, C. J., Wheldon, T. E., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 366 · see citing works

Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum

Kress, M., May, E., Cassingena, R., & May, P. (1979) · Journal of Virology · doi:10.1128/jvi.31.2.472-483.1979 · Cited by 359 · see citing works

The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint

Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 356 · see citing works

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response

Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 344 · see citing works

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

Selivanova, G., Iotsova, V., Okan, İ., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343 · see citing works

Identification of a Minimal Transforming Domain of p53: Negative Dominance through Abrogation of Sequence-Specific DNA Binding

Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 341 · see citing works

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · see citing works

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · see citing works

Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus

Mowat, M. R. A., Cheng, A., Kimura, N., Bernstein, A., & Benchimol, S. (1985) · Nature · doi:10.1038/314633a0 · Cited by 320 · see citing works

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 320 · see citing works

Clinical Overview of MDM2/X-Targeted Therapies

Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315 · see citing works

p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products

Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhræus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 305 · see citing works

A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer

DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B. B., Ribeiro, R. C., Zambetti, G. P., & Kriwacki, R. W. (2001) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 293 · see citing works

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

Valente, L. J., Gray, D. H. D., Michalak, E. M., Hofbauer, J. P., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 292 · see citing works

The rebel angel: mutant p53 as the driving oncogene in breast cancer

Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 287 · see citing works

Next-generation sequencing to guide cancer therapy

Gagan, J., & Allen, E. M. V. (2015) · Genome Medicine · doi:10.1186/s13073-015-0203-x · Cited by 284 · see citing works

A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer

Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L. B., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 283 · see citing works

Li-Fraumeni syndrome: cancer risk assessment and clinical management

McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 279 · see citing works

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

Hanel, W. G., Marchenko, N. D., Xu, S., Yu, S., Weng, W., & Moll, U. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.17 · Cited by 278 · see citing works

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272 · see citing works

ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53

Courtois-Cox, S., Verhaegh, G. W. C. T., North, S., Luciani, M. G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 264 · see citing works

TP53 and gastric carcinoma: A review

Fenoglio‐Preiser, C. M., Wang, J., Stemmermann, G. N., & Noffsinger, A. E. (2003) · Human Mutation · doi:10.1002/humu.10180 · Cited by 252 · see citing works

Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247 · see citing works

Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene

Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 245 · see citing works

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · see citing works

Small molecule induced reactivation of mutant p53 in cancer cells

Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 235 · see citing works

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Li, L., Hoog, J., Goiffon, R., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 224 · see citing works

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L., Salehi, F., Lin, D., Chung, B. P., Hatfield, G. W., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223 · see citing works

The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families

Achatz, M. I., Olivier, M., Calvez‐Kelm, F. L., Martel‐Planche, G., Lopes, A., Rossi, B. M., Ashton‐Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 218 · see citing works

Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways

Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210 · see citing works

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210 · see citing works

Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53

Teufel, D. P., Freund, S. M. V., Bycroft, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702010104 · Cited by 207 · see citing works

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202 · see citing works

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

Fontemaggi, G., Dell’Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., Terrenato, I., Mottolese, M., Muti, P. C., Domany, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1669 · Cited by 195 · see citing works

Activation of the cryptic DNA binding function of mutant forms of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 189 · see citing works

Mutant p53 reactivation by small molecules makes its way to the clinic

Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 180 · see citing works

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160 · see citing works

How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?

Chan, W. M., Siu, W. Y., Lau, A. W. S., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 159 · see citing works

Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway

Tarapore, P., Horn, H. F., Tokuyama, Y., & Fukasawa, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204424 · Cited by 158 · see citing works

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

Brachmann, R. K., Yu, K., Eby, Y. J., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 156 · see citing works

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

Sarig, R., Rivlin, N., Brosh, R., Bornstein, C., Kamer, I., Ezra, O., Molchadsky, A., Goldfinger, N., Brenner, O. J., & Rotter, V. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100797 · Cited by 155 · see citing works

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Schuler, P. J., Harasymczuk, M., Visús, C., DeLeo, A. B., Trivedi, S., Lei, Y. L., Argiris, A. E., Gooding, W. E., Butterfield, L. H., Whiteside, T. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2617 · Cited by 152 · see citing works

Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity

Candau, R., Scolnick, D. M., Darpino, P., Ying, C. Y., Halazonetis, T. D., & Berger, S. L. (1997) · Oncogene · doi:10.1038/sj.onc.1201244 · Cited by 152 · see citing works

COTI-2, a novel small molecule that is active against multiple human cancer cell linesin vitroandin vivo

Salim, K. Y., Vareki, S. M., Danter, W. R., San‐Marina, S., & Koropatnick, J. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 152 · see citing works

Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression

Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 149 · see citing works

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · see citing works

Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

Wang, W., Takimoto, R., Rastinejad, F., & El‐Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 144 · see citing works

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139 · see citing works

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)

Tan, B. S., Tiong, K. H., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.191 · Cited by 136 · see citing works

Targeting p53 for enhanced radio- and chemo-sensitivity

Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 134 · see citing works

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

Wang, Y., Suh, Y., Fuller, M. Y., Jackson, J. G., Xiong, S., Terzian, T., Quintás‐Cardama, A., Bankson, J. A., El‐Naggar, A. K., & Lozano, G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44504 · Cited by 132 · see citing works

Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression

Nozaki, M., Tada, M., Kobayashi, H., Zhang, C. L., Sawamura, Y., Abe, H., Ishii, N., & Meir, E. G. V. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.2.124 · Cited by 126 · see citing works

Mutant p53 targeting by the low molecular weight compound STIMA‐1

Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P. L., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 116 · see citing works

Identification of a Minimal Transforming Domain of p53: Negative Dominance through Abrogation of Sequence-Specific DNA Binding

Shaulian, E., Zauberman, A., Ginsberg, D., et al. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581-5592.1992 · Cited by 113 · see citing works

High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene

Lavigueur, A., Maltby, V., Mock, D., et al. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982-3991.1989 · Cited by 113 · see citing works

Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

Reihsaus, E., Kohler, M., Kraiss, S., Oren, M., & Montenarh, M. (1990) · PubMed · Cited by 109 · see citing works

A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis

Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., Dasmahapatra, B., & Weller, M. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402301 · Cited by 107 · see citing works

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

Demma, M. J., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R. R., Mallams, A. K., Doll, R. J., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107 · see citing works

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth

Aggarwal, M., Saxena, R., Sinclair, E., Fu, Y., Jacobs, A., Dyba, M., Wang, X., Cruz, I., Berry, D., Kallakury, B., et al. (2016) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2016.48 · Cited by 101 · see citing works

Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members

Lomax, M. E., Barnes, D. M., Hupp, T. R., Picksley, S. M., & Camplejohn, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201974 · Cited by 100 · see citing works

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma

Kang, H. J., Chun, S., Kim, K.-R., Sohn, I., & Sung, C. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072609 · Cited by 98 · see citing works

Design of a molecular support for cryo-EM structure determination

Martin, T. G., Bharat, T. A. M., Joerger, A. C., Bai, X., Praetorius, F., Fersht, A. R., Dietz, H., & Scheres, S. H. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612720113 · Cited by 98 · see citing works

Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo

Lee, M. K., Teoh, W. W., Phang, B. H., Tong, W., Wang, Z. Q., & Sabapathy, K. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.022 · Cited by 97 · see citing works

Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity

Xu, J., Wang, J., Hu, Y., Qian, J., Xu, B., Chen, H., Zou, W., & Fang, J.-Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.75 · Cited by 96 · see citing works

Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation.

Rovinski, B., Munroe, D. G., Peacock, J. W., Mowat, M. R. A., Bernstein, A., & Benchimol, S. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.847 · Cited by 96 · see citing works

Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore

Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 86 · see citing works

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry &amp; Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81 · see citing works

Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity

Shi, L. M., Myers, T. G., Fan, Y., O'Connor, P. M., Paull, K. D., Friend, S. H., & Weinstein, J. N. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.2.241 · Cited by 78 · see citing works

The evolution of thymic lymphomas in p53 knockout micePreprint

Dudgeon, C., Chan, C. H., Kang, W., Sun, Y., Emerson, R., Robins, H. S., & Levine, A. J. (2014) · Genes & Development · doi:10.1101/gad.252148.114 · Cited by 77 · see citing works

Restoration of wild‐type conformation and activity of a temperature‐sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE‐1

North, S., Pluquet, O., Maurici, D., Ghissassi, F. E., & Hainaut, P. L. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10038 · Cited by 75 · see citing works

Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs

Vikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75 · see citing works

Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11

Noll, J. E., Jeffery, J., Al‐Ejeh, F., Kumar, R., Khanna, K. K., Callen, D. F., & Neilsen, P. M. (2011) · Oncogene · doi:10.1038/onc.2011.456 · Cited by 75 · see citing works

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Tal, P., Eizenberger, S., Cohen, E., Goldfinger, N., Pietrokovski, S., Oren, M., & Rotter, V. (2016) · Oncotarget · doi:10.18632/oncotarget.7857 · Cited by 74 · see citing works

Energy requirement for degradation of tumor-associated protein p53.

Gronostajski, R. M., Goldberg, A. L., & Pardee, A. B. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.442 · Cited by 73 · see citing works

p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation

Itahana, Y., Ke, H., & Zhang, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805696200 · Cited by 73 · see citing works

Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model

Kucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-464x.2010.07676.x · Cited by 70 · see citing works

Does p53 status influence tumor response to anticancer therapies?

Pirollo, K. F., Bouker, K. B., & Chang, E. H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200007000-00002 · Cited by 64 · see citing works

Dissecting functional roles of p53 N‐terminal transactivation domains by microarray expression analysis

Ohki, R., Kawase, T., Ohta, T., Ichikawa, H., & Taya, Y. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00375.x · Cited by 60 · see citing works

Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis

Heinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W., & Tolstonog, G. V. (2007) · International Journal of Cancer · doi:10.1002/ijc.23317 · Cited by 59 · see citing works

Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

Haupt, S., Agostino, S. D., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, G., & Haupt, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4010 · Cited by 59 · see citing works

Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.

El-Hizawi, S., Lagowski, J. P., Kulesz-Martin, M. F., & Albor, A. (2002) · PubMed · Cited by 56 · see citing works

Dosage‐dependent dominance over wild‐type p53 of a mutant p53 isolated from nasopharyngeal carcinoma 1

Sun, Y., Dong, Z., Nakamura, K., & Colburn, N. H. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344492 · Cited by 54 · see citing works

Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression

Nozaki, M., Tada, M., Kobayashi, H., Zhang, C.-L., Sawamura, Y., Abe, H., Ishii, N., & Meir, E. G. V. (1999) · Neuro-Oncology · doi:10.1215/s1522851798000179 · Cited by 53 · see citing works

Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock‐in (Hupki) mouse model

Kucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07676.x · Cited by 50 · see citing works

The N-Terminally Truncated p53 Isoform △40p53 Influences Prognosis in Mucinous Ovarian Cancer

Hofstetter, G., Berger, A., Berger, R., Zorić, A., Braicu, E. I., Reimer, D., Fiegl, H., Marth, C., Zeimet, A. G., Ulmer, H., et al. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31823ca031 · Cited by 46 · see citing works

Prognostic implications of circulating anti-p53 antibodies in lung cancer - a review

Kumar, S., Mohan, A., & Guleria, R. (2009) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2008.01019.x · Cited by 41 · see citing works

The Contrived Mutant p53 Oncogene – Beyond Loss of Functions

Sabapathy, K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00276 · Cited by 41 · see citing works

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays

Tan, B. X., Brown, C. J., Ferrer, F. J., Yuen, T. Y., Quah, S. T., Chan, B. H., Jansson, A. E., Teo, H., Nordlund, P., & Lane, D. P. (2015) · Scientific Reports · doi:10.1038/srep12116 · Cited by 40 · see citing works

Simple identification of dominant p53 mutants by a yeast functional assay

Inga, A. (1997) · Carcinogenesis · doi:10.1093/carcin/18.10.2019 · Cited by 40 · see citing works

p53 and Hereditary Cancer

Merino, D. M., & Malkin, D. M. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_1 · Cited by 39 · see citing works

Energy Requirement for Degradation of Tumor-Associated Protein p53

Gronostajski, R. M., Goldberg, A. L., & Pardee, A. B. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.442-448.1984 · Cited by 39 · see citing works

Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis

Phang, B. H., Othman, R., Bougeard, G., Chia, R. H., Frébourg, T., Tang, C. L., Cheah, P. Y., & Sabapathy, K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510043112 · Cited by 37 · see citing works

COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.

Zhou, X., Wang, X. W., Xu, L., Hagiwara, K., Nagashima, M., Wolkowicz, R., Zurer, I., Rotter, V., & Harris, C. C. (1999) · PubMed · Cited by 37 · see citing works

Integrity of the 1,25-dihydroxyvitamin D3 receptor in bone, lung, and other cancers

Miller, C. W., Roberta Morosetti, A., Campbell, M. J., Mendoza, S., & Koeffler, H. P. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199708)19:4 · Cited by 33 · see citing works

Awaiting a New Era of Cancer Immunotherapy

Hong, C. W., & Zeng, Q. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0063 · Cited by 32 · see citing works

The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo

Lee, M. K., & Sabapathy, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.022822 · Cited by 31 · see citing works

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Iyer, S. V., Parrales, A., Begani, P., Narkar, A., Adhikari, A. S., Martinez, L. A., & Iwakuma, T. (2015) · Oncotarget · doi:10.18632/oncotarget.6634 · Cited by 30 · see citing works

Deletion of 5′-coding Sequences of the Cellular p53 Gene in Mouse Erythroleukemia: A Novel Mechanism of Oncogene Regulation

Rovinski, B., Munroe, D. G., Peacock, J., et al. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.847-853.1987 · Cited by 30 · see citing works

Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice

Donehower, L. A. (2014) · Human Mutation · doi:10.1002/humu.22507 · Cited by 29 · see citing works

Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils

Galea, C. A., Bowman, P., & Kriwacki, R. W. (2005) · Protein Science · doi:10.1110/ps.051622005 · Cited by 27 · see citing works

Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53

Bristow, R. G., Peacock, J. W., Jang, A., Kim, J., Hill, R. P., & Benchimol, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206405 · Cited by 23 · see citing works

A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.

Plummer, S. J., Santibanez‐Koref, M., Kurosaki, T., Liao, S., Noble, B., Fain, P. R., Anton‐Culver, H., & Casey, G. (1994) · PubMed · Cited by 20 · see citing works

The application of gene therapy in China.

Peng, Z., Qing, Y., & Li, B. (2008) · PubMed · Cited by 19 · see citing works

Fischer 344-Tp53 knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis

Hansen, S. A., Hart, M. L., Busi, S. B., Parker, T. W., Goerndt, A., Jones, K. B., Amos-Landgraf, J. M., & Bryda, E. C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025767 · Cited by 19 · see citing works

P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH

Forslund, A., Kressner, U., Lönnroth, C., Andersson, M., Lindmark, G. E., & Lundholm, K. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.2.409 · Cited by 16 · see citing works

p53 as an Effector or Inhibitor of Therapy ResponsePreprint

Ablain, J., Poirot, B., Esnault, C., Lehmann‐Che, J., & de Thé, H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15 · see citing works

Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein

Bromley, D., Bauer, M. R., Fersht, A. R., & Daggett, V. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw035 · Cited by 14 · see citing works

Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas

Semczuk, A., Schneider‐Stock, R., & Szewczuk, W. (2010) · Oncology · doi:10.1159/000314353 · Cited by 12 · see citing works

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays

Lin, C., Chen, I.-C., Huang, C., Hu, F., Kuo, W., Kuo, K., Wang, C., Wu, P., Chang, D., Wang, M., et al. (2015) · Scientific Reports · doi:10.1038/srep17879 · Cited by 12 · see citing works

PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein

Stuber, G., Flaberg, E., Petrányi, G., Ötvös, R. H.-G., Rökaeus, N., Kashuba, E., Wiman, K. G., Klein, G., & Székely, L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-23 · Cited by 8 · see citing works

p53-independentWAF1 induction by ACNU in human glioblastoma cells

Aoki, H., Ohnishi, K., Wang, X., Takahashi, A., Ohnishi, T., Nakamura, M., & Sakaki, T. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199803)21:3 · Cited by 7 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C. Y., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 850 · see citing works

Drugging p53 in cancer: one protein, many targets

Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works

Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants

Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636 · see citing works

Somatic mutations precede acute myeloid leukemia years before diagnosis

Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619 · see citing works

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works

Regulating tumor suppressor genes: post-translational modifications

Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

MDM2 inhibition: an important step forward in cancer therapy

Konopleva, M. Y., Martinelli, G., Daver, N. G., Papayannidis, C., Wei, A. H., Higgins, B., Ott, M., Mascarenhas, J. O., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376 · see citing works

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378 · see citing works

Targeting p53 for the treatment of cancer

Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 351 · see citing works

Deubiquitinase-targeting chimeras for targeted protein stabilization

Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344 · see citing works

The approved gene therapy drugs worldwide: from 1998 to 2019

Ma, C., Wang, Z.-L., Xu, T., He, Z., & Wei, Y.-Q. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 331 · see citing works

The Role of p53 Signaling in Colorectal Cancer

Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 332 · see citing works

The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic

Zhang, W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 320 · see citing works

The complexity of p53-mediated metabolic regulation in tumor suppression

Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 260 · see citing works

Mutant p53 in cancer therapy—the barrier or the path

Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 244 · see citing works

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223 · see citing works

Control of metabolism by p53 – Cancer and beyond

Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 219 · see citing works

Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer

Liu, H., Liu, Y., Yang, F., Zhang, L., Zhang, F., Hu, X., Shao, Z., & Li, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa130 · Cited by 205 · see citing works

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Sun, H., Liu, S. M., Zhou, J., Xu, J., Zhang, H.-K., Yan, H., Huan, J., Dai, P., Xu, C., Su, J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102990 · Cited by 205 · see citing works

Translating p53-based therapies for cancer into the clinic

Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 198 · see citing works

Towards the overcoming of anticancer drug resistance mediated by p53 mutations

Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 176 · see citing works

Immunomodulation by anticancer cell cycle inhibitors

Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163 · see citing works

The many faces of p53: something for everyone

Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163 · see citing works

TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works

Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Lo, W. M., Parkhurst, M. R., Robbins, P. F., Tran, E., Lu, Y., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D. C., Malekzadeh, P., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0686 · Cited by 156 · see citing works

Current developments of targeting the p53 signaling pathway for cancer treatment

Huang, J. L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107720 · Cited by 155 · see citing works

p53 and metabolism: from mechanism to therapeutics

Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 152 · see citing works

Polyamines: their significance for maintaining health and contributing to diseases

Xuan, M., Gu, X., Li, J., Huang, D., Chen, X., & He, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01373-0 · Cited by 159 · see citing works

How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance

Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 139 · see citing works

Understanding p53 functions through p53 antibodies

Sabapathy, K., & Lane, D. P. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz010 · Cited by 139 · see citing works

Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration

Kolb, D., Kolishetti, N., Surnar, B., Sarkar, S., Guin, S., Shah, A. S., & Dhar, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b10037 · Cited by 137 · see citing works

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133 · see citing works

p53 as a hub in cellular redox regulation and therapeutic target in cancer

Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · see citing works

Emerging Roles of p53 Family Members in Glucose Metabolism

Itahana, Y., & Itahana, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030776 · Cited by 120 · see citing works

Spaceflight and simulated microgravity suppresses macrophage development via altered RAS/ERK/NFκB and metabolic pathways

Shi, L., Tian, H., Wang, P., Li, L., Zhang, Z., Zhang, J., & Zhao, Y. X. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0346-6 · Cited by 115 · see citing works

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma

Best, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108 · see citing works

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

Boullosa, L. F., Loenhout, J. V., Flieswasser, T., Waele, J. D., Hermans, C., Lambrechts, H. A. J., Cuypers, B., Laukens, K., Bartholomeus, E., Siozopoulou, V., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101949 · Cited by 111 · see citing works

Acute Myeloid Leukemia: The Good, the Bad, and the Ugly

Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 111 · see citing works

Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients

Hassin, O., Nataraj, N. B., Shreberk‐Shaked, M., Aylon, Y., Yaeger, R. D., Fontemaggi, G., Mukherjee, S., Maddalena, M., Seligman, A., Iancu, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30481-7 · Cited by 110 · see citing works

Current status and new treatment approaches in TP53 mutated AML

Hunter, A. M., & Sallman, D. A. (2019) · Best Practice &amp; Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102 · see citing works

p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma

Jin, S., Yang, X., Li, J., Yang, W., Ma, H., & Zhang, Z. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0993-3 · Cited by 109 · see citing works

A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity

Yan, S., Yan, J., Liu, D., Li, X., Kang, Q., You, W., Zhang, J., Wang, L., Tian, Z., Lu, W., et al. (2021) · Theranostics · doi:10.7150/thno.59020 · Cited by 107 · see citing works

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

Schulz‐Heddergott, R., & Moll, U. M. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 105 · see citing works

An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells

Uddin, M. B., Roy, K. R., Hosain, S. B., Khiste, S., Hill, R. A., Jois, S. D. S., Zhao, Y., Tackett, A. J., & Liu, Y. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.014 · Cited by 104 · see citing works

Strategies for targeting undruggable targets

Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 102 · see citing works

The Interplay Between Tumor Suppressor p53 and Hypoxia Signaling Pathways in Cancer

Zhang, C., Liu, J., Wang, J., Zhang, T., Xu, D., Hu, W., & Feng, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648808 · Cited by 97 · see citing works

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 97 · see citing works

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94 · see citing works

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593383 · Cited by 92 · see citing works

URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers

Ding, Z., Pan, Y., Shang, T., Jiang, T., Lin, Y., Yang, C., Pang, S., Cui, X., Wang, Y., Feng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41852-z · Cited by 92 · see citing works

Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6

Sicari, D., Fantuz, M., Bellazzo, A., Valentino, E., Apollonio, M., Pontisso, I., Cristino, F. D., Ferro, M. D., Bicciato, S., Sal, G. D., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0878-3 · Cited by 91 · see citing works

Drugging “undruggable” genes for cancer treatment: Are we making progress?

Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 85 · see citing works

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

Canale, M., Andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., Delmonte, A., Crinò, L., Bronte, G., & Ulivi, P. (2022) · Cancers · doi:10.3390/cancers14051143 · Cited by 93 · see citing works

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations

Funk, J. S., Klimovich, M., Drangenstein, D., Pielhoop, O., Hunold, P., Borowek, A., Noeparast, M., Pavlakis, E., Neumann, M. M., Balourdas, D.-I., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02039-4 · Cited by 92 · see citing works

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84 · see citing works

The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases

Anbarasan, T., & Bourdon, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246257 · Cited by 81 · see citing works

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 84 · see citing works

Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen

Wu, D., Gallagher, D. T., Gowthaman, R., Pierce, B. G., & Mariuzza, R. A. (2020) · Nature Communications · doi:10.1038/s41467-020-16755-y · Cited by 77 · see citing works

The Role of p53 in Progression of Cutaneous Squamous Cell Carcinoma

Piipponen, M., Riihilä, P., Nissinen, L. M., & Kähäri, V. (2021) · Cancers · doi:10.3390/cancers13184507 · Cited by 79 · see citing works

Functions of p53 in pluripotent stem cells

Fu, X., Wu, S., Li, B., Xu, Y., & Liu, J. (2019) · Protein & Cell · doi:10.1007/s13238-019-00665-x · Cited by 78 · see citing works

Cancer Stemness: p53 at the Wheel

Ghatak, D., Ghosh, D. D., & Roychoudhury, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604124 · Cited by 75 · see citing works

The Mettl3 epitranscriptomic writer amplifies p53 stress responses

Raj, N., Wang, M., Seoane, J. A., Zhao, R. L., Kaiser, A. M., Moonie, N. A., Demeter, J., Boutelle, A. M., Kerr, C. H., Mulligan, A. S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.010 · Cited by 74 · see citing works

The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

Liu, J., Zhang, C., Xu, D., Zhang, T., Chang, C., Wang, J., Liu, J., Zhang, L., Haffty, B. G., Zong, W., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164354 · Cited by 74 · see citing works

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 71 · see citing works

Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2

Yang, W., Liu, W., Li, X., Yan, J., & He, W. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.05.009 · Cited by 70 · see citing works

Computer-Aided Drug Discovery for Undruggable Targets

Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 69 · see citing works

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Stockhammer, P., Grant, M. J., Wurtz, A., Foggetti, G., Expósito, F., Gu, J., Zhao, H., Choi, J., Chung, S. T., Li, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.001 · Cited by 67 · see citing works

Patterns of mutations in TP53 mutated AML

Welch, J. S. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.09.010 · Cited by 67 · see citing works

Role of Dietary Antioxidants in p53‐Mediated Cancer Chemoprevention and Tumor Suppression

Merlin, J. P. J., Rupasinghe, H. P. V., Dellaire, G., & Murphy, K. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9924328 · Cited by 68 · see citing works

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 71 · see citing works

p53’s Extended Reach: The Mutant p53 Secretome

Pavlakis, E., & Stiewe, T. (2020) · Biomolecules · doi:10.3390/biom10020307 · Cited by 65 · see citing works

Ceramide Signaling and p53 Pathways

Jeffries, K. A., & Krupenko, N. I. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.04.011 · Cited by 64 · see citing works

Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance

Xu, J., Patel, N. H., & Gewirtz, D. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238991 · Cited by 64 · see citing works

Structural and Drug Targeting Insights on Mutant p53

Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 63 · see citing works

A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications

Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 60 · see citing works

p53 partial loss-of-function mutations sensitize to chemotherapy

Klimovich, B., Merle, N., Neumann, M. M., Elmshäuser, S., Nist, A., Mernberger, M., Kazdal, D. N., Stenzinger, A., Timofeev, O. N., & Stiewe, T. (2021) · Oncogene · doi:10.1038/s41388-021-02141-5 · Cited by 61 · see citing works

Targeting mutant p53: a key player in breast cancer pathogenesis and beyond

Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 66 · see citing works

Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis

Chou, C.-W., Lin, C., Hsiao, T.-H., Lo, C.-C., Hsieh, C.-Y., Huang, C.-C., & Sher, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-56532-6 · Cited by 60 · see citing works

Structural diversity of p63 and p73 isoforms

Osterburg, C., & Dötsch, V. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00975-4 · Cited by 63 · see citing works

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress

Deben, C., Deschoolmeester, V., Waele, J. D., Jacobs, J., den Bossche, J. V., Wouters, A., Peeters, M., Rolfo, C. D., Smits, E., Lardon, F., et al. (2018) · Cancers · doi:10.3390/cancers10040126 · Cited by 59 · see citing works

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties

Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9155 · Cited by 56 · see citing works

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

Li, S., Wang, A., Wu, Y., He, S., Wen, S., Zhao, M., Zhu, Y., Hu, X., Luo, Y., & Wang, G. (2023) · Immunological Reviews · doi:10.1111/imr.13274 · Cited by 57 · see citing works

Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease

Blandino, G., Valenti, F., Sacconi, A., & Agostino, S. D. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.011 · Cited by 59 · see citing works

Mutant p53 in cell-cell interactionsPreprint

Pilley, S. E., Rodríguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 54 · see citing works

ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 59 · see citing works

T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy

Sim, M. J. W., & Sun, P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833017 · Cited by 52 · see citing works

p53/MicroRNA-34 axis in cancer and beyond

Pan, W. D., Chai, B., Langping, L., Lü, Z., & Ma, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15155 · Cited by 52 · see citing works

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine

Hwang, L., Phang, B. H., Liew, O. W., Iqbal, J., Koh, X. H., Koh, X. Y., Othman, R., Xue, Y., Richards, M., Lane, D. P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.11.112 · Cited by 52 · see citing works

p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression

Efe, G., Dunbar, K. J., Sugiura, K., Cunningham, K. M., Carcamo, S., Karaiskos, S., Tang, Q., Cruz‐Acuña, R., Resnick‐Silverman, L., Peura, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0601 · Cited by 52 · see citing works

Cancer therapeutic targeting using mutant–p53-specific siRNAs

Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50 · see citing works

The role and mechanism of NAT10‐mediated ac4C modification in tumor development and progression

Gu, Z., Zou, L., Pan, X., Yu, Y., Liu, Y., Zhang, Z., Liu, J., Mao, S., Zhang, J., Guo, C., et al. (2024) · MedComm · doi:10.1002/mco2.70026 · Cited by 52 · see citing works

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 50 · see citing works

The Tumor Microenvironment: Signal Transduction

Zhang, X., Ma, H., Gao, Y., Liang, Y., Du, Y., Hao, S., & Ni, T. (2024) · Biomolecules · doi:10.3390/biom14040438 · Cited by 55 · see citing works

Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes

Singh, S. P., Bhaskar, R., Ghosh, S., Yarlagadda, B., Singh, D. K. K., Verma, P., Sengupta, S., Mladenov, M. I., Hadzi‐Petrushev, N., Stojchevski, R., et al. (2025) · Cancers · doi:10.3390/cancers17071082 · Cited by 55 · see citing works

Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets

Lu, J., Ding, Y., Chen, Y., Jiang, J., Chen, Y., Huang, Y., Wu, M., Li, C., Kong, M., Zhao, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24170-0 · Cited by 47 · see citing works

TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia

Bomben, R., Rossi, F. M., Vit, F., Bittolo, T., D’Agaro, T., Zucchetto, A., Tissino, E., Pozzo, F., Vendramini, E., Degan, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0701 · Cited by 48 · see citing works

Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S., & Crown, J. P. (2022) · Cancers · doi:10.3390/cancers14184499 · Cited by 48 · see citing works

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

Chen, A. P., Kummar, S., Moore, N., Rubinstein, L., Zhao, Y., Williams, P. M., Palmisano, A., Sims, D., Coyne, G. O., Rosenberger, C. L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00372 · Cited by 47 · see citing works

Targeting mutant p53 for cancer therapy

Oren, M., Tal, P., & Rotter, V. (2016) · Aging · doi:10.18632/aging.100992 · Cited by 23 · see citing works

Mutant p53 in Cancer Progression and Targeted Therapies

Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 220 · see citing works

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84 · see citing works

p53: from understanding its structure to advances in therapeutic targeting

Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 25 · see citing works

Molecularly targeted therapies for p53-mutant cancers

Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 81 · see citing works